Patients’, physicians’, nurses’, and pharmacists’ preferences on the characteristics of biologic agents used in the treatment of rheumatic diseases

References

• BoonenAvan der LindenSMThe burden of ankylosing spondylitisJ Rheumatol Suppl20067841117042055
   PubMedGoogle Scholar
• GeuskensGABurdorfAHazesJMConsequences of rheumatoid arthritis for performance of social roles – a literature reviewJ Rheumatol20073461248126017407220
   PubMed Web of Science ®Google Scholar
• GladmanDDStafford-BradyFChangCHLewandowskiKRussellMLLongitudinal study of clinical and radiological progression in psoriatic arthritisJ Rheumatol19901768098122388203
   PubMed Web of Science ®Google Scholar
• HunscheEChancellorJVBruceNThe burden of arthritis and non-steroidal anti-inflammatory treatment. A European literature reviewPharmacoeconomics2001191115
   Web of Science ®Google Scholar
• CortesiPAScaloneLD’AngiolellaLSystematic literature review on economic implications and pharmacoeconomic issues of psoriatic arthritisClin Exp Rheumatol2012304 Suppl 73S126S13123072771
   PubMed Web of Science ®Google Scholar
• FurneriGMantovaniLGBelisariASystematic literature review on economic implications and pharmacoeconomic issues of rheumatoid arthritisClin Exp Rheumatol2012304 Suppl 73S72S8423072761
   PubMed Web of Science ®Google Scholar
• OlivieriICortesiPAde PortuSLong-term costs and outcomes in psoriatic arthritis patients not responding to conventional therapy treated with tumour necrosis factor inhibitors: the extension of the Psoriatic Arthritis Cost Evaluation (PACE) studyClin Exp Rheumatol2016341687526633622
   PubMed Web of Science ®Google Scholar
• PallaITriesteLTaniCA systematic literature review of the economic impact of ankylosing spondylitisClin Exp Rheumatol2012304 Suppl 73S136S14123072824
   PubMed Web of Science ®Google Scholar
• HjardemEHetlandMLOstergaardMKroghNSKvienTKDanish Database for Biological Therapies in Rheumatology Study GPrescription practice of biological drugs in rheumatoid arthritis during the first 3 years of post-marketing use in Denmark and Norway: criteria are becoming less stringentAnn Rheum Dis20056481220122315640272
   PubMed Web of Science ®Google Scholar
• KavanaughACohenSCushJJThe evolving use of tumor necrosis factor inhibitors in rheumatoid arthritisJ Rheumatol200431101881188415468347
   PubMed Web of Science ®Google Scholar
• KobeltGAndlin-SobockiPBrophySJönssonLCalinABraunJThe burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade)Rheumatology20044391158116615226514
   PubMed Web of Science ®Google Scholar
• SmolenJSLandewéRBijlsmaJEULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 updateAnn Rheum Dis201776696097728264816
   PubMed Web of Science ®Google Scholar
• CoatesLCKavanaughAMeasePJGroup for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 treatment recommendations for psoriatic arthritisArthritis Rheumatol20166851060107126749174
   PubMed Web of Science ®Google Scholar
• GossecLSmolenJSRamiroSEuropean League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 updateAnn Rheum Dis201675349951026644232
   PubMed Web of Science ®Google Scholar
• BartonJLPatient preferences and satisfaction in the treatment of rheumatoid arthritis with biologic therapyPatient Prefer Adherence2009333534420016797
   PubMed Web of Science ®Google Scholar
• AugustovskiFBeratarrecheaAIrazolaVPatient preferences for biologic agents in rheumatoid arthritis: a discrete-choice experimentValue Health201316238539323538191
   PubMed Web of Science ®Google Scholar
• KromerCSchaarschmidtMLSchmiederAHerrRGoerdtSPeitschWKPatient preferences for treatment of psoriasis with biologicals: a discrete choice experimentPLoS One2015106e012912026058083
   PubMed Web of Science ®Google Scholar
• HazlewoodGSBombardierCTomlinsonGTreatment preferences of patients with early rheumatoid arthritis: a discrete-choice experimentRheumatology201655111959196827477807
   PubMed Web of Science ®Google Scholar
• RotheryCBojkeLRichardsonGA discrete choice experiment to explore patients’ willingness to risk disease relapse from treatment withdrawal in psoriatic arthritisClin Rheumatol201635122967297427796664
   PubMed Web of Science ®Google Scholar
• CantiniFNiccoliLNanniniCSecond-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitisSemin Arthritis Rheum201747218319228413099
   PubMed Web of Science ®Google Scholar
• DuresEHewlettSLordJImportant treatment outcomes for patients with psoriatic arthritis: a multisite qualitative studyPatient201710445546228229377
   PubMedGoogle Scholar
• Torre-AlonsoJCQueiroRComellasMLizánLBlanchCPatient-reported outcomes in European spondyloarthritis patients: a systematic review of the literaturePatient Prefer Adherence20181273374729780239
   PubMed Web of Science ®Google Scholar
• D’AngeloSTramontanoGGilioMLeccesePOlivieriIReview of the treatment of psoriatic arthritis with biological agents: choice of drug for initial therapy and switch therapy for non-respondersOpen Access Rheumatol20179212828280401
   PubMed Web of Science ®Google Scholar
• HifingerMHiligsmannMRamiroSInfluence of disease activity on RA treatment choices in countries with restricted access to expensive, innovative drugs: a discrete choice experiment among rheumatologistsRMD Open201732e00045328912960
   PubMedGoogle Scholar
• FaggioliGScaloneLMantovaniLGBorghettiFStellaAPREFER study groupPreferences of patients, their family caregivers and vascular surgeons in the choice of abdominal aortic aneurysms treatment options: the PREFER studyEur J Vasc Endovasc Surg2011421263421334928
   PubMed Web of Science ®Google Scholar
• NollaJMRodríguezMMartin-MolaEPatients’ and rheumatologists’ preferences for the attributes of biological agents used in the treatment of rheumatic diseases in SpainPatient Prefer Adherence2016101101111327382258
   PubMed Web of Science ®Google Scholar
• ScaloneLMantovaniLGBorghettiFvon MackensenSGringeriAPatients’, physicians’, and pharmacists’ preferences towards coagulation factor concentrates to treat haemophilia with inhibitors: results from the COHIBA StudyHaemophilia200915247348619347988
   PubMed Web of Science ®Google Scholar
• WenHRalph SchumacherHLiXComparison of expectations of physicians and patients with rheumatoid arthritis for rheumatology clinic visits: a pilot, multicenter, international studyInt J Rheum Dis201215438038922898218
   PubMed Web of Science ®Google Scholar
• WillekePBeckerHWassenbergSPavenstädtHJacobiAMPatient/rheumatologist evaluation of infusion treatment for rheumatoid arthritisZ Rheumatol2011702343232236232238
   Google Scholar
• HakimZPathakDSModelling the EuroQol data: a comparison of discrete choice conjoint and conditional preference modellingHealth Econ19998210311610342724
   PubMed Web of Science ®Google Scholar
• RyanMA role for conjoint analysis in technology assessment in health care?Int J Technol Assess Health Care199915344345710874373
   PubMed Web of Science ®Google Scholar
• Reed JohnsonFLancsarEMarshallDConstructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task ForceValue Health201316131323337210
   PubMed Web of Science ®Google Scholar
• MoiaMMantovaniLGCarpenedoMPatient preferences and willingness to pay for different options of anticoagulant therapyIntern Emerg Med20138323724322926743
   PubMed Web of Science ®Google Scholar
• ScaloneLCarminatiMBonhoefferPPatients’ and physicians’ needs, experiences and preferences in the treatment of right ventricular outflow tract dysfunctionItal J Public Health2012927383
   Google Scholar
• ScaloneLCiampichiniRFagiuoliSComparing the performance of the standard EQ-5D 3L with the new version EQ-5D 5L in patients with chronic hepatic diseasesQual Life Res20132271707171623192232
   PubMed Web of Science ®Google Scholar
• LouviereJJHensherDASwaitJDStated Choice Methods Analysis and ApplicationCambridge, UKCambridge University Press2000
   Google Scholar
• World Medical AssociationWMA Declaration of Helsinki – ethical principles for medical research involving human subjects2013 Available from: https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/
   Google Scholar
• ManskiCFThe structure of random utility modelsTheory Decis197783229254
   Web of Science ®Google Scholar
• EfronBTibshiraniRJAn Introduction to the BootstrapBoca RatonCRC Press1994
   Google Scholar
• DEMO ISTAT Available from: http://demo.istat.it/pop2014/index.htmlAccessed October 5, 2017
   Google Scholar
• BolgeSCGorenABrownDGinsbergSAllenIOpenness to and preference for attributes of biologic therapy prior to initiation among patients with rheumatoid arthritis: patient and rheumatologist perspectives and implications for decision makingPatient Prefer Adherence2016101079109027390518
   PubMed Web of Science ®Google Scholar
• DesplatsMPascartTJelinGAre abatacept and tocilizumab intravenous users willing to switch for the subcutaneous route of administration? A questionnaire-based studyClin Rheumatol20173661395140028255739
   PubMed Web of Science ®Google Scholar
• HifingerMHiligsmannMRamiroSPatients’ preferences and economic considerations play an important role in treatment decisions: a discrete choice experiment among rheumatologistsRheumatology2017561687628028156
   PubMed Web of Science ®Google Scholar
• HuynhTKØstergaardAEgsmoseCMadsenORPreferences of patients and health professionals for route and frequency of administration of biologic agents in the treatment of rheumatoid arthritisPatient Prefer Adherence20148939924470758
   PubMed Web of Science ®Google Scholar
• ScarpatoSAntivalleMFavalliEGPatient preferences in the choice of anti-TNF therapies in rheumatoid arthritis. Results from a questionnaire survey (RIVIERA study)Rheumatology201049228929419920093
   PubMed Web of Science ®Google Scholar
• SylwestrzakGLiuJStephensonJJRuggieriAPDevriesAConsidering patient preferences when selecting anti-tumor necrosis factor therapeutic optionsAm Health Drug Benefits201472718124991392
   PubMedGoogle Scholar